Quality of Life with Advanced Metastatic Prostate Cancer

被引：24
|
作者：
Resnick, Matthew J. [1 ,2 ]
Penson, David F. [1 ,2 ]
机构：
[1] Vanderbilt Univ, Dept Urol Surg, Ctr Surg Qual & Outcomes Res, Nashville, TN 37232 USA
[2] VA Tennessee Valley Geriatr Res Educ & Clin Ctr G, Nashville, TN 37212 USA
来源：
UROLOGIC CLINICS OF NORTH AMERICA | 2012年 / 39卷 / 04期
关键词：
Prostate cancer; Metastatic; Castrate-resistant; Quality of life; Functional status; Palliation; ANDROGEN-DEPRIVATION THERAPY; PAINFUL BONE METASTASES; SICKNESS IMPACT PROFILE; MITOXANTRONE PLUS PREDNISONE; HEALTH-STATUS; PHASE-II; RADIONUCLIDE TREATMENT; ASYMPTOMATIC MEN; RANDOMIZED-TRIAL; ZOLEDRONIC ACID;
D O I：
10.1016/j.ucl.2012.07.007
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The health-related quality-of-life (HRQOL) implications of advanced metastatic prostate cancer are variable. There are several different HRQOL instruments that measure domains germane to patients with advanced metastatic disease. The burden of prostate cancer is inversely related to the magnitude of HRQOL declines. Treatment with androgen deprivation therapy commonly results in HRQOL declines that have served as the impetus for intermittent therapy. Conversely, chemotherapeutic agents have been associated with improvements in functional status for men with castrate-resistant disease. Emerging therapies may result in significant HRQOL improvements in this population, and careful prospective evaluation of patient-reported outcomes will be required.
引用
收藏
页码：505 / +
页数：12
相关论文
共 50 条
  • [41] Quality of life aspects of treatment options for localized and locally advanced prostate cancer
    Anderson, J
    EUROPEAN UROLOGY, 2001, 40 : 24 - 30
  • [42] Quality of life and emotional distress in advanced prostate cancer survivors undergoing chemotherapy
    Trask P.C.
    Health and Quality of Life Outcomes, 2 (1)
  • [43] Validation in Spain of the Quality of Life Questionnaire PROSQOLI in Patients with Advanced Prostate Cancer
    Fernandez-Arjona, M.
    de la Cruz, G.
    Delgado, J. A.
    Malet, J. M.
    Portillo, J. A.
    ACTAS UROLOGICAS ESPANOLAS, 2012, 36 (07): : 410 - 417
  • [44] QUALITY OF LIFE AMONG GERMAN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Wolff, J. M.
    Donatz, V
    Klier, J.
    Erhardt, W.
    Dass, R. N.
    Geiges, G.
    VALUE IN HEALTH, 2012, 15 (07) : A431 - A431
  • [45] Lifestyle and health-related quality of life in men with metastatic prostate cancer.
    Sheill, Grainne
    Brady, Lauren
    Guinan, Emer
    Hussey, Juliette
    Hevey, David
    Vlajnic, Tatjana
    Casey, Orla
    Baird, Anne-Marie
    Cahill, Fidelma
    Van Hemelrijck, Mieke
    Peat, Nicola
    Rudman, Sarah
    Lynch, Thomas
    Manecksha, Rustom P.
    Hayes, Brian
    Cunningham, Moya
    Grogan, Liam
    McCaffrey, John
    O'Donnell, Dearbhaile M.
    McDermott, Ray
    Leary, John O.
    Finn, Stephen P.
    CANCER RESEARCH, 2018, 78 (16) : 56 - 57
  • [46] Management of advanced/metastatic prostate cancer: 2000 update
    Hussain, A
    Dawson, N
    ONCOLOGY-NEW YORK, 2000, 14 (12): : 1677 - +
  • [47] Radical prostatectomy for locally advanced and metastatic prostate cancer
    Veeratterapillay, R.
    Goonewardene, S. S.
    Barclay, J.
    Persad, R.
    Bach, C.
    ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND, 2017, 99 (04) : 259 - 264
  • [48] Treatment of oligo- and advanced metastatic prostate cancer
    Hadaschik, B. A.
    Merseburger, A. S.
    UROLOGE, 2020, 59 (06): : 657 - 658
  • [49] Use of abiraterone acetate in advanced metastatic prostate cancer
    Marquez Fernandez, E.
    Marmesat Rodas, B.
    Quesada Sanz, M. P.
    Gallego Galisteo, M.
    Ramos Baez, J. J.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 994 - 994
  • [50] Current treatment of locally advanced and metastatic prostate cancer
    Ponholzer A.
    Steinbacher F.
    Madersbacher S.
    Schramek P.
    Wiener Medizinische Wochenschrift, 2011, 161 (15-16) : 377 - 381
12345